PRIMACYT
Cell Culture Technology

EHCP Equine Hepatocytes Cryopreserved Plateable Cell Specification – Certificate of Analysis (CoA)	
Lot EH151217-2	Batch release: Oct 23, 2019; updated Oct 27, 2021

Species: Equus caballus	Gender: female Age: 8 months
Diagnosis: degenerative knee point disease, Ablatio retinae on both eyes	
Cryopreservation: Date: December 17, 2015 Amount per vial: 10 x 10^6 cells	Thawing: n=2 Post-thaw viability: 95.0 ± 0.6 % Post-thaw yield per vial: 5.6 ± 0.6 x 10^6 cells Recovery: 56 %
Phase contrast on day 5 after thawing 	Phase contrast on day 13 after thawing 
Recommended seeding density on collagen-coated plates: 400.000 cells per well (24well plate). Culture in Human Hepatocyte Maintenance Medium (HHMM). Not suitable for use in suspension cultures.	
Note: Yield, viability, recovery and activity assays were performed at PRIMACYT using PRIMACYT's manual for thawing, plating and culture of primary cryopreserved hepatocytes.	

CYP P450 activity in culture after thawing:	pmol/(mg × min)	X-fold induction
Ethoxyresorufin-O-deethylation:		
Induction with 25 µM beta-naphthoflavone for 72 h	day 5-8: 7.2 ± 0.1 day 12-15: 2.8 ± 0.1	4.4 2.7
Induction with 50 µM beta-naphthoflavone for 72 h	day 5-8: 12.9 ± 3.0 day 12-15: 4.3 ± 0.5	7.9 4.1

E-mail: info@primacyt.com, Tel.: +49 (0) 385-3993-600, Fax: +49 (0) 385-3993-602

Stimulation of urea release with NH_4Cl and Ornithine for 24 h at day 4 and day 8 in culture.



Shipping Temperature: below -135 °C
Storage Temperature: at -150 °C or in the vapour phase of LN_2

This product should be considered as potential biohazard. Only intended for *in vitro* use. Not for therapeutic purposes.

Updated by: A. Ullrich

Verified by: T. Krimmling / D. Runge